NG-350A / Akamis Bio  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NG-350A / Akamis Bio
FORTIFY, NCT05165433: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours

Recruiting
1a/1b
198
Europe, US
NG-350A plus Pembrolizumab
Akamis Bio, Merck Sharp & Dohme LLC
Epithelial Tumor, Metastatic Cancer
03/25
05/25
FORTITUDE, NCT03852511: First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)

Completed
1
28
US
NG-350A
PsiOxus Therapeutics Ltd
Metastatic Cancer, Epithelial Tumor
02/22
02/22
REVOLUTION, NCT04787991: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Active, not recruiting
1
45
US
Nivolumab (Cohort A), Opdivo, Ipilimumab (Cohort A, B and C), Yervoy, Hydroxychloroquine (HCQ) (Cohort B), Plaquenil, Nab-paclitaxel (nP) (Cohort A, B and C), Abraxane, Gemcitabine (gem) (Cohort A, B and C), Gemzar, NG350A (Cohort C)
Cancer Insight, LLC, Bristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio
Metastatic Pancreatic Adenocarcinoma
10/24
01/25
FORTRESS, NCT06459869: NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Not yet recruiting
1
30
NA
NG-350A IV administration, Capecitabine oral administration, Radiotherapy
Akamis Bio
Locally Advanced Rectal Cancer (LARC)
02/26
01/29

Download Options